.alpha.-amylase mutants
AssigneeNovo Nordisk A/S
InventorsAllan Svendsen, Torben Vedel Borchert, Henrik Bisg.ang.rd-Frantzen
Life of this patent
Estimating the term…
Abstract
The invention relates to a variant of a parent Termamyl-like .alpha.-amylase, which variant has a-amylase activity and exhibits an alteration in at least one of the following properties relative to said parent a-amylase: substrate specificity, substrate binding, substrate cleavage pattern, thermal stability, pH/activity profile, pH/stability profile, stability towards oxidation, Ca.sup.2+ dependency and specific activity.
Claims92
A variant of a parent Termamyl-like .alpha.-amylase, wherein said variant has .alpha.-amylase activity and exhibits an alteration relative to said parent .alpha.-amylase in at least one property selected from the group consisting of substrate specificity, substrate binding, substrate cleavage pattern, thermal stability, pH-activity profile, pH-stability profile, stability towards oxidation, Ca.sup.2+ dependency and specific activity;
- said variant comprising at least one mutation corresponding to a mutation in the amino acid sequence of SEQ ID NO:2 selected from the group consisting of:
- a) single substitutions of A181E,D,Q,N,T or V;
- I201W,F, or L;
- Q9K,L, or E;
- F11R,K, or E;
- E12Q;
- D100N, or L;
- V101H,R,K,D,E, or F;
- I103H or K;
- N104R or K;
- H105R,K,D,E,W, or F;
- L196D,E,F, or Y;
- I212D, or E;
- L230H or K;
- A232H,F or V;
- V233D;
- K234L;
- I236N,H,D, or E;
- L241R,K,D,E, or F;
- A260S;
- W263H;
- Q264R,D,K,A,L,S,T or E;
- N265K,R, A,S,T or D;
- A269R,D, or E;
- L270R,K,H,D, or E;
- V283H, or D;
- F284H;
- D285N or L;
- V286R,K,H,D, or E;
- Y290R or K;
- V312R,K,D, or E;
- F323H;
- D325N;
- N326K,H,D, or L;
- H327Q,N,E,D, or F;
- Q330L, or E;
- G332D;
- Q333H,E, or L;
- S334A,V,T,L,I, or D;
- L335G,A,S,T, or N;
- R375E;
- T338D or E;
- Q360K,R, or E;
- D365N;
- G371D or R;
- H140Y;
- H142Y;
- H159Y;
- R169I,L,F, or T;
- R173I,L,F, or T;
- H156D;
- I212F;
- A209L,T;
- or V208I;
- N172R,H, or K;
- N188P;
- N190L or F;
- H205C;
- D207Y;
- E211Q;
- b) multiple substitutions of H140D and H142R;
- H140K and H142D;
- H142Y and H156Y;
- Q264S and N265Y;
- H156Y and A181T and A209V;
- or H156Y and A181T and N190F and A209V and Q264S;
- c) any substitution at positions R169, R173, H91, K389, R483, A181, H205, D207, or E211;
- d) deletion of three amino acids within the sequence T369-I377;
- e) deletions of D372, S373, and Q374;
- f) replacement of T369-I377 with a sequence selected from the group consisting of I-P-T-H-S-V, I-P-T-H-G-V, and I-P-Q-Y-N-I;
- g) deletion of A1 and N2 and substitution of L3V and M15T and R23K and S29A and A30E and Y31H and A33S and E34D and H35I and H156Y and A181T and A209V;
- h) deletion of A1 and N2 and substitution of L3V and M15T and R23K and S29A and A30E and Y31H and A33S and E34D and H35I and H156Y and A181T and N190F and A209V;
- and
- i) deletion of A1 and N2 and substitution of L3V and M15T and R23K and S29A and A30E and Y31H and A33S and E34D and H35I and H156Y and A181T and N190F and A209V and Q264S.
A polypeptide comprising
- (a) a first peptide sequence consisting of residues 1-33 of SEQ ID NO:4 fused to
- (b) a second peptide sequence consisting of a variant of residues 36-483 of SEQ ID NO:2, wherein said second peptide sequence has substitutions H156Y and A181T and N190F and A209V and Q264S relative to SEQ ID NO:2.
Dependencies are inferred from the claim text.